Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Atherosclerosis ; 284: 50-58, 2019 05.
Artigo em Inglês | MEDLINE | ID: mdl-30875493

RESUMO

BACKGROUND AND AIMS: COX-2-selective inhibitors have been associated with an increased risk of cardiovascular complications, and their impact on atherosclerosis (AS) remains controversial. The proinflammatory COX-2 and 5-LO pathways both play essential roles in AS and related cardiovascular diseases. Previous clinical studies have provided evidence of the ability of COX-2-selective inhibitors to shunt AA metabolism from the COX-2 pathway to the 5-LO pathway. In this study, the effects of celecoxib, a selective COX-2 inhibitor, on AS and the COX-2 and 5-LO pathways were investigated in vivo and in vitro. METHODS: Male ApoE-/- mice fed a western-type diet for 18 weeks and cultured mouse RAW264.7 macrophages stimulated with 1 µg/mL LPS for 24 h were used in this study. RESULTS: In ApoE-/- mice, intragastric administration of celecoxib (80 mg/kg/d) for 18 weeks significantly increased aortic atherosclerotic lesion area but had no effect on hyperlipidemia. In addition, celecoxib significantly lowered TNF-α and PGE2 levels but increased both LTB4 and CysLTs levels in aortic tissues. In LPS-stimulated RAW264.7 macrophages, pretreatment with 8 µmol/L celecoxib for 1 h significantly lowered the TNF-α, NO, and PGE2 levels but increased the LTB4 and CysLTs levels. Celecoxib also decreased the protein and mRNA expression of COX-2 but increased the expression of 5-LO and LTC4S in both ApoE-/- mouse aortic tissues and LPS-stimulated RAW264.7 macrophages. CONCLUSION: The COX-2-selective inhibitor celecoxib can aggravate atherogenesis, an effect that may be related to upregulation of LTs via a 5-LO pathway shunt.


Assuntos
Aterosclerose/induzido quimicamente , Celecoxib/efeitos adversos , Inibidores de Ciclo-Oxigenase 2/efeitos adversos , Leucotrienos/fisiologia , Células RAW 264.7/fisiologia , Regulação para Cima/efeitos dos fármacos , Animais , Apolipoproteínas E/genética , Lipopolissacarídeos/farmacologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Células RAW 264.7/efeitos dos fármacos , Índice de Gravidade de Doença
2.
J Endod ; 44(6): 997-999, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29680727

RESUMO

INTRODUCTION: To date, no study has investigated the antiresorptive property of lunasin. Hence, the present study aimed to assess the ability of lunasin to inhibit the osteoclast formation using RAW 264.7 cells. We hypothesized that lunasin is able to inhibit osteoclast formation. METHODS: In the present study, the murine monocytic cell line RAW 264.7 was induced to differentiate into mature osteoclasts in the presence of recombinant receptor activator of nuclear factor kappa-B ligand. Tartrate-resistant acid phosphatase, a marker of osteoclasts, was used to identify osteoclasts. Cell lines were divided into different groups and exposed to different concentrations of 50 µmol/L, 75 µmol/L, and 100 µmol/L active and inactive lunasin. The control group was RAW 264.7 cells with receptor activator of nuclear factor kappa-B ligand. Tartrate-resistant acid phosphatase-positive cells of 3 or more nuclei, indicative of mature osteoclasts, were counted by 3 observers. The mean number of the data collected was analyzed using 1-way analysis of variance and the multiple comparison post hoc Bonferroni correction. RESULTS: There was a significant difference in the reduction of osteoclast formation in all the active lunasin groups (P < .001) compared with the control group and the inactive lunasin group (P < .001). CONCLUSIONS: Considering the suppressive effect of lunasin on osteoclastogenesis, the use of lunasin as a potential antiresorptive agent can be evaluated in future studies.


Assuntos
Conservadores da Densidade Óssea/farmacologia , Osteoclastos/efeitos dos fármacos , Células RAW 264.7/efeitos dos fármacos , Receptor Ativador de Fator Nuclear kappa-B/efeitos dos fármacos , Proteínas de Soja/farmacologia , Animais , Diferenciação Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Camundongos , Osteoclastos/fisiologia , Células RAW 264.7/fisiologia , Receptor Ativador de Fator Nuclear kappa-B/fisiologia
3.
Med Sci Monit ; 23: 5462-5471, 2017 Nov 17.
Artigo em Inglês | MEDLINE | ID: mdl-29146892

RESUMO

BACKGROUND The aim of this study was to explore the role of intermedin and its mechanism in cholesterol efflux of macrophage THP-1 and RAW264.7 cell lines in atherosclerosis (AS). MATERIAL AND METHODS ApoE-/- mice were fed with a high-fat diet, and the concentrations of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured. The lipidoses of the aortic sinus were analyzed by hematoxylin and eosin staining, and the cAMP level was detected by enzyme-linked immunosorbent assay (ELISA). The expressions of ATP-binding cassette transporter (ABCA1) were tested by real-time PCR and Western blot analysis. RESULTS IMD decreased serum TC and LDL-C, and increased serum HDL-C level in apoE-/- mice and attenuated AS plaque areas. In vitro, IMD increased intracellular cAMP concentration in a dose-dependent manner in THP-1 and RAW264.7 cell lines, which enhanced the expression of ABCA1 and increased cholesterol efflux rate. However, this effect was inhibited by PKAI in the RAW 264.7 cell line but not in the THP-1 cell line. CONCLUSIONS IMD can ameliorate the development of AS in ApoE-/- mice and regulate cholesterol balance in the RAW264.7 cell line through the cAMP-PKA pathway.


Assuntos
Aterosclerose/tratamento farmacológico , Neuropeptídeos/farmacologia , Alcaloides de Pirrolizidina/metabolismo , Alcaloides de Pirrolizidina/farmacocinética , Transportador 1 de Cassete de Ligação de ATP/metabolismo , Transportadores de Cassetes de Ligação de ATP/metabolismo , Animais , Apolipoproteínas E/metabolismo , Aterosclerose/metabolismo , Transporte Biológico , Colesterol/metabolismo , HDL-Colesterol/sangue , LDL-Colesterol/sangue , AMP Cíclico/metabolismo , Subunidade RIalfa da Proteína Quinase Dependente de AMP Cíclico/metabolismo , Proteínas Quinases Dependentes de AMP Cíclico/efeitos dos fármacos , Proteínas Quinases Dependentes de AMP Cíclico/metabolismo , Dieta Hiperlipídica , Humanos , Macrófagos/metabolismo , Camundongos , Camundongos Knockout , Neuropeptídeos/metabolismo , Placa Aterosclerótica/tratamento farmacológico , Células RAW 264.7/efeitos dos fármacos , Células RAW 264.7/fisiologia , Células THP-1/efeitos dos fármacos , Células THP-1/fisiologia , Triglicerídeos/sangue
4.
PLoS One ; 12(4): e0174899, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28380006

RESUMO

We have reported a new phenomenon in acute wound healing following the use of intracellular ATP delivery-extremely rapid tissue regeneration, which starts less than 24 h after surgery, and is accompanied by massive macrophage trafficking, in situ proliferation, and direct collagen production. This unusual process bypasses the formation of the traditional provisional extracellular matrix and significantly shortens the wound healing process. Although macrophages/monocytes are known to play a critical role in the initiation and progression of wound healing, their in situ proliferation and direct collagen production in wound healing have never been reported previously. We have explored these two very specific pathways during wound healing, while excluding confounding factors in the in vivo environment by analyzing wound samples and performing in vitro studies. The use of immunohistochemical studies enabled the detection of in situ macrophage proliferation in ATP-vesicle treated wounds. Primary human macrophages and Raw 264.7 cells were used for an in vitro study involving treatment with ATP vesicles, free Mg-ATP alone, lipid vesicles alone, Regranex, or culture medium. Collagen type 1α 1, MCP-1, IL-6, and IL-10 levels were determined by ELISA of the culture supernatant. The intracellular collagen type 1α1 localization was determined with immunocytochemistry. ATP-vesicle treated wounds showed high immunoreactivity towards BrdU and PCNA antigens, indicating in situ proliferation. Most of the cultured macrophages treated with ATP-vesicles maintained their classic phenotype and expressed high levels of collagen type 1α1 for a longer duration than was observed with cells treated with Regranex. These studies provide the first clear evidence of in situ macrophage proliferation and direct collagen production during wound healing. These findings provide part of the explanation for the extremely rapid tissue regeneration, and this treatment may hold promise for acute and chronic wound care.


Assuntos
Trifosfato de Adenosina/uso terapêutico , Cicatrização/efeitos dos fármacos , Trifosfato de Adenosina/administração & dosagem , Animais , Quimiocina CCL2/metabolismo , Colágeno Tipo I/metabolismo , Cadeia alfa 1 do Colágeno Tipo I , Humanos , Interleucina-10/metabolismo , Interleucina-6/metabolismo , Lipossomos , Macrófagos/efeitos dos fármacos , Macrófagos/fisiologia , Camundongos , Células RAW 264.7/efeitos dos fármacos , Células RAW 264.7/fisiologia , Fatores de Tempo
5.
Biochem Biophys Res Commun ; 487(2): 247-254, 2017 05 27.
Artigo em Inglês | MEDLINE | ID: mdl-28412360

RESUMO

Electroporation is the most widely employed method of gene transfer into macrophages which are hard to transfect. RAW 264.7 is a widely used cell line for studying macrophage responses. Electroporation of RAW 264.7 cells with commercial reagents although very efficient is expensive necessitating the development of cost effective alternatives. In this study, we have formulated an economical electroporation buffer for electroporation of RAW 264.7 cells compatible with commercial nucleofector apparatus. We observed that supplementation of membrane fusogenic agents such as Ficoll, PEG and membrane resealing agent, poloxamer P188, enhanced the transfection efficiency of macrophages to a level comparable to the commercially available solutions thereby providing us a cost effective solution for genetic manipulation of macrophages especially in large numbers.


Assuntos
Meios de Cultivo Condicionados/economia , Engenharia de Proteínas/economia , Células RAW 264.7/fisiologia , Proteínas Recombinantes/economia , Transfecção/economia , Transfecção/métodos , Animais , Técnicas de Cultura Celular por Lotes/economia , Técnicas de Cultura Celular por Lotes/métodos , Soluções Tampão , Análise Custo-Benefício/economia , Análise Custo-Benefício/métodos , Meios de Cultivo Condicionados/metabolismo , Índia , Camundongos , Engenharia de Proteínas/métodos , Células RAW 264.7/citologia , Proteínas Recombinantes/biossíntese
6.
PLoS One ; 11(8): e0161282, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27536885

RESUMO

Zerumbone is a sesquiterpene present in Zinger zerumbet. Many studies have demonstrated its marked anti-inflammatory and anti-carcinogenesis activities. Recently, we showed that zerumbone binds to numerous proteins with scant selectivity and induces the expression of heat shock proteins (HSPs) in hepatocytes. To dampen proteo-toxic stress, organisms have a stress-responsive molecular machinery, known as heat shock response. Heat shock factor 1 (HSF1) plays a key role in this protein quality control system by promoting activation of HSPs. In this study, we investigated whether zerumbone-induced HSF1 activation contributes to its anti-inflammatory functions in stimulated macrophages. Our findings showed that zerumbone increased cellular protein aggregates and promoted nuclear translocation of HSF1 for HSP expression. Interestingly, HSF1 down-regulation attenuated the suppressive effects of zerumbone on mRNA and protein expressions of pro-inflammatory genes, including inducible nitric oxide synthase and interlukin-1ß. These results suggest that proteo-stress induced by zerumbone activates HSF1 for exhibiting its anti-inflammatory functions.


Assuntos
Anti-Inflamatórios/farmacologia , Proteínas de Ligação a DNA/fisiologia , Agregação Patológica de Proteínas/induzido quimicamente , Sesquiterpenos/farmacologia , Fatores de Transcrição/fisiologia , Animais , Western Blotting , Ensaio de Imunoadsorção Enzimática , Proteínas de Choque Térmico HSP72/metabolismo , Fatores de Transcrição de Choque Térmico , Interleucina-1beta/metabolismo , Interleucina-6/metabolismo , Camundongos , Óxido Nítrico Sintase Tipo II/metabolismo , Agregação Patológica de Proteínas/fisiopatologia , Células RAW 264.7/efeitos dos fármacos , Células RAW 264.7/fisiologia , Interferência de RNA/fisiologia , Reação em Cadeia da Polimerase em Tempo Real , Fator de Necrose Tumoral alfa/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...